Chief Financial Officer

Chief Comm & Corp Aff Officer

Chairman & CEO

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Institution	Shares	Value	Change
Robeco Institutional Asset Management B.V	3,459,893	$437M	INCREASED
Assenagon Asset Management	2,287,888	$289M	INCREASED
Swedbank AB	1,903,177	$240M	DECREASED
New York State Teachers Retirement System	988,492	$125M	DECREASED
Handelsbanken Fonder AB	975,089	$123M	DECREASED

Insider	Type	Shares	Value	Date
Andrew D Dickinson (Chief Financial Officer)	SELL	3,000	$390K	2026-07-15
Johanna Mercier (Chief Comm & Corp Aff Officer)	SELL	3,000	$390K	2026-07-15
O'Day Daniel Patrick (Chairman & CEO)	SELL	3,100	$394K	2026-07-01
O'Day Daniel Patrick (Chairman & CEO)	SELL	11,900	$2M	2026-07-01
Andrew D Dickinson (Chief Financial Officer)	SELL	3,000	$376K	2026-06-15

Gilead Sciences Inc (GILD) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades